Colistin in animals: a high risk for resistance selection in Europe?

Richez, Pascal; Burch, David

doi:10.1136/vr.i381

Cited by 5 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several susceptibility testing methods are used in pigs to determine colistin MIC against bacterial strains of porcine origin (Rhouma et al, 2016a), without specific clinical breakpoints for colistin against Enterobacteriaceae after its oral use in swine medicine (Boyen et al, 2010; Richez and Burch, 2016). Such information is of crucial importance for identifying the colistin PD index that is predictive of microbiological efficacy and outcome and to establish the quantitative relationship between PK and PD parameters (Papich, 2014).…”

Section: Pharmacokinetics and Pharmacodynamics (Pk And Pd) Of Colistimentioning

confidence: 99%

Colistin in Pig Production: Chemistry, Mechanism of Antibacterial Action, Microbial Resistance Emergence, and One Health Perspectives

et al. 2016

View full text Add to dashboard Cite

Colistin (Polymyxin E) is one of the few cationic antimicrobial peptides commercialized in both human and veterinary medicine. For several years now, colistin has been considered the last line of defense against infections caused by multidrug-resistant Gram-negative such as Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Colistin has been extensively used orally since the 1960s in food animals and particularly in swine for the control of Enterobacteriaceae infections. However, with the recent discovery of plasmid-mediated colistin resistance encoded by the mcr-1 gene and the higher prevalence of samples harboring this gene in animal isolates compared to other origins, livestock has been singled out as the principal reservoir for colistin resistance amplification and spread. Co-localization of the mcr-1 gene and Extended-Spectrum-β-Lactamase genes on a unique plasmid has been also identified in many isolates from animal origin. The use of colistin in pigs as a growth promoter and for prophylaxis purposes should be banned, and the implantation of sustainable measures in pig farms for microbial infection prevention should be actively encouraged and financed. The scientific research should be encouraged in swine medicine to generate data helping to reduce the exacerbation of colistin resistance in pigs and in manure. The establishment of guidelines ensuring a judicious therapeutic use of colistin in pigs, in countries where this drug is approved, is of crucial importance. The implementation of a microbiological withdrawal period that could reduce the potential contamination of consumers with colistin resistant bacteria of porcine origin should be encouraged. Moreover, the management of colistin resistance at the human-pig-environment interface requires the urgent use of the One Health approach for effective control and prevention. This approach needs the collaborative effort of multiple disciplines and close cooperation between physicians, veterinarians, and other scientific health and environmental professionals. This review is an update on the chemistry of colistin, its applications and antibacterial mechanism of action, and on Enterobacteriaceae resistance to colistin in pigs. We also detail and discuss the One Health approach and propose guidelines for colistin resistance management.

show abstract

Section: Pharmacokinetics and Pharmacodynamics (Pk And Pd) Of Colistimentioning

confidence: 99%

Colistin in Pig Production: Chemistry, Mechanism of Antibacterial Action, Microbial Resistance Emergence, and One Health Perspectives

et al. 2016

View full text Add to dashboard Cite

show abstract

“…For example, it was suggested that “the contribution of animals to the overall problem of human resistance is likely to be very small” (Bywater, 2004). Others were likewise doubtful (Richez & Burch, 2016; Wallinga & Burch, 2013), whilst one eminent microbiologist (Phillips, 2003, 2007) directly challenged the suggestion that veterinary medicine, rather than human medicine, was the primary factor responsible for AMR in humans. He further suggested that restrictions on animal use would actually be ineffective.…”

Section: The Prudent Use Of Antimicrobials: Residues In Food Antimicmentioning

confidence: 99%

A history of antimicrobial drugs in animals: Evolution and revolution

Lees

Pelligand

Giraud

et al. 2020

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

The evolutionary process of antimicrobial drug (AMD) uses in animals over a mere eight decades (1940–2020) has led to a revolutionary outcome, and both evolution and revolution are ongoing, with reports on a range of uses, misuses and abuses escalating logarithmically. As well as veterinary therapeutic perspectives (efficacy, safety, host toxicity, residues, selection of drug, determination of dose and measurement of outcome in treating animal diseases), there are also broader, nontherapeutic uses, some of which have been abandoned, whilst others hopefully will soon be discontinued, at least in more developed countries. Although AMD uses for treatment of animal diseases will continue, it must: (a) be sustainable within the One Health paradigm; and (b) devolve into more prudent, rationally based therapeutic uses. As this review on AMDs is published in a Journal of Pharmacology and Therapeutics, its scope has been made broader than most recent reviews in this field. Many reviews have focused on negative aspects of AMD actions and uses, especially on the question of antimicrobial resistance. This review recognizes these concerns but also emphasizes the many positive aspects deriving from the use of AMDs, including the major research‐based advances underlying both the prudent and rational use of AMDs. It is structured in seven sections: (1) Introduction; (2) Sulfonamide history; (3) Nontherapeutic and empirical uses of AMDs (roles of agronomists and veterinarians); (4) Rational uses of AMDs (roles of pharmacologists, clinicians, industry and regulatory controls); (5) Prudent use (residue monitoring, antimicrobial resistance); (6) International and inter‐disciplinary actions; and (7) Conclusions.

show abstract

“…CMS is administered to pigs, veal calves, and poultry to treat and prevent diarrhea caused by E. coli (called colibacillosis) and Salmonella spp. The amount of CMS used varies by EU member states, with Denmark considered to be a low user, France a moderate user and Germany a high user [20]. The reason for this discrepancy is unclear but different farming practices between countries is not a very plausible explanation.…”

Section: How Is Colistin Resistance Being Spread By Agricultural Use?mentioning

confidence: 99%

On the path to untreatable infections: colistin use in agriculture and the end of ‘last resort’ antibiotics

Watkins¹,

Smith²

2016

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Colistin in animals: a high risk for resistance selection in Europe?

Cited by 5 publications

References 8 publications

Colistin in Pig Production: Chemistry, Mechanism of Antibacterial Action, Microbial Resistance Emergence, and One Health Perspectives

Colistin in Pig Production: Chemistry, Mechanism of Antibacterial Action, Microbial Resistance Emergence, and One Health Perspectives

A history of antimicrobial drugs in animals: Evolution and revolution

On the path to untreatable infections: colistin use in agriculture and the end of ‘last resort’ antibiotics

Contact Info

Product

Resources

About